Feedback / Questions
M300 - Mestag Therap
https://www.globenewswire.com/news-release/2024/04/08/2859417/0/en/Mestag-Presents-Preclinical-Data-at-AACR-on-its-M300-Program-a-Conditionally-Active-LTBR-Agonist-Designed-to-Induce-Tertiary-Lymphoid-Structures-in-Tumors.html
Apr 8, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next